Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: Rationale and design of randomised, double-blind, placebo-controlled trial

Current Medical Research and Opinion

Volumn 28, Issue 2, 2012, Pages 231-239

  Cooper, Cyrus ^a   Reginster, Jean Yves ^b   Chapurlat, Roland ^c   Christiansen, Claus ^d   Genant, Harry ^e   Bellamy, Nicholas ^f   Bensen, William ^g   Navarro, Federico ^h   Badurski, Janusz ⁱ   Nasonov, Evgeny ^j   Chevalier, Xavier ^k   Sambrook, Philip N ^l  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d CCBR   (Denmark)

^e SYNARC INC   (United States)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g MCMASTER UNIVERSITY   (Canada)

^h HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

ⁱ Centre of Osteoporosis and Osteoarticular Diseases   (Poland)

^j V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^k HENRI MONDOR HOSPITAL   (France)

^l ROYAL NORTH SHORE HOSPITAL   (Australia)

more..

Author keywords

DMOAD; Joint space width; Knee osteoarthritis; Knee radiograph; Randomized clinical trial; Strontium ranelate; Structure modifying treatment

Indexed keywords

BIOLOGICAL MARKER; PLACEBO; STRONTIUM RANELATE;

ADULT; ARTICLE; ARTICULAR CARTILAGE; BONE REMODELING; CARTILAGE DEGENERATION; CARTILAGE MATRIX; CAUCASIAN; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; JOINT CAVITY; KNEE OSTEOARTHRITIS; KNEE PAIN; KNEE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; WESTERN ONTARIO AND MCMASTER UNIVERSITITES OSTEOARTHRITIS INDEX;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KNEE JOINT; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOARTHRITIS, KNEE; RESEARCH DESIGN; THIOPHENES;

EID: 84856435528     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.648758     Document Type: Article

References (41)

1. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35
2. Dawson J, Linsell L, Zondervan K, et al. Epidemiology of hip and knee pain and its impact on overall health status in older adults. Rheumatology (Oxford) 2004;43:497-504 (Pubitemid 38489368)
3. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010;18:476-99
4. Matthews GL, Hunter DJ. Emerging drugs for osteoarthritis. Expert Opin Emerg Drugs 2011;16:479-91
5. Bingham CO III, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54:3494-507 (Pubitemid 44737161)
6. Spector TD, Conaghan PG, Buckland-Wright JC, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005;7:R625-33
7. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795-808 (Pubitemid 43290918)
8. Hellio Le Graverand-Gastineau MP. OA clinical trials: current targets and trials for OA. Choosing molecular targets: what have we learned and where we are headed? Osteoarthritis Cartilage 2009;17:1393-401
9. Brandt KD, Mazzuca SA, Katz BP, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2005;52:2015-25 (Pubitemid 40994324)
10. Kwan TS, Lajeunesse D, Pelletier JP, et al. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol 2010;24:51-70
11. Karsdal MA, Leeming DJ, Dam EB, et al. Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage 2008;16:638-46
12. Marie PJ. Strontium ranelate: new insights into its dual mode of action. Bone 2007;40:S5-8 (Pubitemid 46562594)
13. Brennan TC, Rybchyn MS, Green W, et al. Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 2009;157: 1291-300
14. Chattopadhyay N, Quinn SJ, Kifor O, et al. The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol 2007;74:438-47 (Pubitemid 46970843)
15. Chang W, Tu C, Chen TH, et al. Expression and signal transduction of calcium-sensing receptors in cartilage and bone. Endocrinology 1999;140:5883-93 (Pubitemid 30645377)
16. Atkins GJ, Welldon KJ, Halbout P, et al. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 2009;20:653-64
17. Caverzasio J. Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms. Bone 2008;42:1131-6
18. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68 (Pubitemid 38133766)
19. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22 (Pubitemid 40686329)
20. Tat SK, Pelletier JP, Mineau F, et al. Strontium ranelate inhibits key factors affecting bone remodelling in human osteoarthritic subchondral bone osteoblasts. Bone 2011;49:559-67
21. Henrotin Y, Labasse A, Zheng SX, et al. Strontium ranelate increases cartilage matrix formation. J Bone Miner Res 2001;16:299-308 (Pubitemid 32105411)
22. Alexandersen P, Karsdal MA, Qvist P, et al. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone 2007;40:218-22 (Pubitemid 44848419)
23. Alexandersen P, Karsdal MA, Byrjalsen I, et al. Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis. Climacteric 2010;14:236-43
24. Bruyere O, Delferriere D, Roux C, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008;67:335-9 (Pubitemid 351281267)
25. Lane NE, Nevitt MC, Genant HK, et al. Reliability of new indices of radiographic osteoarthritis of the hand and hip and lumbar disc degeneration. J Rheumatol 1993;20:1911-18 (Pubitemid 24031597)
26. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49
27. Kellgren MJ. The Epidemiology of Chronic Rheumatism: Atlas of Standard Radiographs, 2nd Oxford, UK: Ingersleben Blackwell Scientific, 1963
28. Kothari M, Guermazi A, Von Ingersleben G, et al. Fixed-flexion radiography of the knee provides reproducible joint space width measurements in osteoarthritis. Eur Radiol 2004;14:1568-73 (Pubitemid 39232885)
29. Gensburger D, Arlot M, Sornay-Rendu E, et al. Radiologic assessment of agerelated knee joint space changes in women: a 4-year longitudinal study. Arthritis Rheum 2009;61:336-43
30. Gensburger D, Roux JP, Arlot M, et al. Influence of blinding sequence of radiographs on the reproducibility and sensitivity to change of joint space width measurement in knee osteoarthritis. Arthritis Care Res (Hoboken) 2010;62:1699-705
31. Felson DT, Nevitt MC. Blinding images to sequence in osteoarthritis: evidence from other diseases. Osteoarthritis Cartilage 2009;17:281-3
32. Botha-Scheepers S, Watt I, Breedveld FC, Kloppenburg M. Reading radiographs in pairs or in chronological order influences radiological progression in osteoarthritis. Rheumatology (Oxford) 2005;44:1452-5 (Pubitemid 41631872)
33. Altman RD, Abadie E, Avouac B, et al. Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthritis Cartilage 2005;13:13-19 (Pubitemid 40104258)
34. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40 (Pubitemid 19037656)
35. Sowers MF, Karvonen-Gutierrez CA, Yosef M, et al. Longitudinal changes of serum COMP and urinary CTX-II predict X-ray defined knee osteoarthritis severity and stiffness in women. Osteoarthritis Cartilage 2009;17: 1609-14
36. Garnero P, Piperno M, Gineyts E, et al. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001;60:619-26 (Pubitemid 32493990)
37. Raynauld JP, Kauffmann C, Beaudoin G, et al. Reliability of a quantification imaging system using magnetic resonance images to measure cartilage thickness and volume in human normal and osteoarthritic knees. Osteoarthritis Cartilage 2003;11:351-60 (Pubitemid 36621845)
38. Peterfy CG, Guermazi A, Zaim S, et al. Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 2004;12:177-90 (Pubitemid 38248067)
39. Emrani PS, Katz JN, Kessler CL, et al. Joint space narrowing and Kellgren-Lawrence progression in knee osteoarthritis: an analytic literature synthesis. Osteoarthritis Cartilage 2008;16:873-82
40. Sawitzke AD, Shi H, Finco MF, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008;58:3183-91
41. Kahan A, Uebelhart D, De VF, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60:524-33